NVCT Nuvectis Pharma, Inc.
Healthcare$10.35-5.39%ClosedMarket Cap: $274.5M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
17.04
P/S
0.00
EV/EBITDA
-8.82
DCF Value
$1.18
FCF Yield
-6.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.8%
ROA
-106.9%
ROIC
-198.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-6.3M | $-6.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-7.6M | $-7.3M | $— | — |
| FY null | $0.00 | NaN% | $-27.6M | $-26.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.8M | $-7.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.6M | $-6.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.6M | $-5.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.4M | $-6.2M | $— | — |
| FY null | $0.00 | NaN% | $-19.8M | $-19.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.4M | $-4.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.6M | $-4.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.4M | $-4.2M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-6.9M | $-6.6M | $-0.42 | — |